title: "Blindly" ADA Dose Escalation to 80 mg Weekly in Crohn's Disease Patients with LOR: Is It Cost Effective or Not?
authors.affiliation: Gastroenterology Unit, Policlinico di Modena, Modena, Italy.
authors.forename: Alessandro
authors.initials: A
authors.lastname: Sartini
authors.forename: Maria
authors.initials: M
authors.lastname: Di Girolamo
authors.forename: Angela
authors.initials: A
authors.lastname: Bertani
authors.forename: Erica
authors.initials: E
authors.lastname: Villa
mesh_terms: D000068879:Adalimumab / Q000627:therapeutic use*; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D003424:Crohn Disease / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male
chemical_list: D000893:Anti-Inflammatory Agents; D000068879:Adalimumab